<DOC>
	<DOC>NCT02694718</DOC>
	<brief_summary>The purpose of this study is to determine the pathological complete tumor response rate.</brief_summary>
	<brief_title>A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirmed locally advanced T3/T4 rectal carcinoma with or without nodal involvement requiring surgery of the primary tumor Eastern Cooperative Oncology Group performance status 02 Adequate values of laboratory parameters Evidence of distant metastases Previous Chemotherapy or immunotherapy for colorectal cancer Previous radiotherapy to the pelvis Preexisting condition which would deter radiotherapy Malignancy within last 5 years, except cured basal cell cancer of the skin and in situ cancer of the cervix Clinically significant cardiac disease or myocardial infarction within the last 12 months Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome Organ allografts Concomitant treatment with brivudine, lamivudine, ribavirin or any other nucleoside analogues Dihydropyrimidine dehydrogenase (DPD) deficiency History of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>